Skip to Main Content

Author Details

Yang Liu
Veracyte inc.
2019
51
18
PMIDPaper TitleJournal TitlePublished Year
36798177Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.Res Sq2023
37595184Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial.JCO Precis Oncol2023
37525535Use of the Decipher genomic classifier among men with prostate cancer in the United States.JNCI Cancer Spectr2023
37857524Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy.J Immunother Cancer2023
37700560Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race-specific luminal-basal and microenvironmental differences.Cancer Commun (Lond)2023
37870965Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.Clin Cancer Res2023
35568781High intratumoral plasma cells content in primary prostate cancer defines a subset of tumors with potential susceptibility to immune-based treatments.Prostate Cancer Prostatic Dis2023
37060201A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.Cancer2023
37021052Anoikis-related long non-coding RNA signatures to predict prognosis and small molecular drug response in cervical cancer.Front Pharmacol2023
37205576Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence.medRxiv2023
36621992Reply by Authors.J Urol2023
36621991Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.J Urol2023
36397716Transcriptomic recurrence score improves recurrence prediction for surgically treated patients with intermediate-risk clear cell kidney cancer.Cancer Med2023
33303244Novel Transcriptomic Interactions Between Immune Content and Genomic Classifier Predict Lethal Outcomes in High-grade Prostate Cancer.Eur Urol2022
35638091Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race.Eur Urol Open Sci2022
35562350MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets.Nat Commun2022
36053178Genomic Testing in Localized Prostate Cancer Can Identify Subsets of African Americans With Aggressive Disease.J Natl Cancer Inst2022
35050721Does Perioperative Testosterone Predict Post-Prostatectomy Genomic Risk Score?J Urol2022
34226663A transcriptomic model for homologous recombination deficiency in prostate cancer.Prostate Cancer Prostatic Dis2022
32417369Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study.Eur Urol Oncol2021
33570548Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial.JAMA Oncol2021
33712636A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer.Sci Rep2021
33568675Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes.Nat Commun2021
33840559Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer.Eur Urol2021
33531653A comparative study of PCS and PAM50 prostate cancer classification schemes.Prostate Cancer Prostatic Dis2021
34083737Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences.Commun Biol2021
33998599Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.J Clin Invest2021
34081076Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer.JAMA Oncol2021
33356482Heterogeneity in Genomic Risk Assessment from Tissue Based Prognostic Signatures Used in the Biopsy Setting and the Impact of Magnetic Resonance Imaging Targeted Biopsy.J Urol2021
33037017Comparative Genomics Reveals Distinct Immune-oncologic Pathways in African American Men with Prostate Cancer.Clin Cancer Res2021
32896505Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer.Clin Genitourin Cancer2021
32192889Prognostic value of the SPOP mutant genomic subclass in prostate cancer.Urol Oncol2020
35050780Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate.JCO Precis Oncol2020
31812633Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy.Urol Oncol2020
32074006A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging.J Urol2020
33299986Diversity in Androgen Receptor Action Among Treatment-naïve Prostate Cancers Is Reflected in Treatment Response Predictions and Molecular Subtypes.Eur Urol Open Sci2020
32585335Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors.Int J Radiat Oncol Biol Phys2020
32895534Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.Nature2020
32461072Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer.Eur Urol2020
32165065Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.Eur Urol2020
30321406The Immune Landscape of Prostate Cancer and Nomination of PD-L2 as a Potential Therapeutic Target.J Natl Cancer Inst2019
31010837Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types.Clin Cancer Res2019
31125117Characterization of transcriptomic signature of primary prostate cancer analogous to prostatic small cell neuroendocrine carcinoma.Int J Cancer2019
30952638Molecular Characterization of Neuroendocrine-like Bladder Cancer.Clin Cancer Res2019
30712971Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.Eur Urol2019
31619281Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.Genome Med2019
31515456Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a <i>de novo</i> low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer.Clin Cancer Res2019
31411980Validation of the Decipher Test for Predicting Distant Metastatic Recurrence in Men with High-risk Nonmetastatic Prostate Cancer 10 Years After Surgery.Eur Urol Oncol2019
31585777Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.Urol Oncol2019
31243370FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes.Nature2019
  • 1 - 50 of 51

Recommended Authors

Lydia Y Liu
University of Toronto
Career Start Year 2018
Number of shared co-authors 5
Renu Jeyapala
Toronto Metropolitan University
Career Start Year 2018
Number of shared co-authors 1
Michael Sigouros
Caryl and Israel Englander Institute for Precision Medicine
Career Start Year 2017
Number of shared co-authors 15
Rohan Bareja
Case Western Reserve University
Career Start Year 2017
Number of shared co-authors 15
Jingbin Zhang
GenomeDx Biosciences Inc.
Career Start Year 2017
Number of shared co-authors 25
Vincent Huang
Ontario Institute for Cancer Research
Career Start Year 2016
Number of shared co-authors 11
Natalie Kurganovs
Australian Prostate Cancer Research Centre Epworth
Career Start Year 2015
Number of shared co-authors 4
Wei Yuan
The Institute for Cancer Research
Career Start Year 2015
Number of shared co-authors 15
Daniel H Hovelson
Michigan Center for Translational Pathology, University of Michigan ann arbor
Career Start Year 2014
Number of shared co-authors 20
Stephanie A Wankowicz
University of California San Francisco
Career Start Year 2014
Number of shared co-authors 16
Joshua Armenia
Oncology R&D
Career Start Year 2013
Number of shared co-authors 19
Ekaterina Olkhov-Mitsel
University of Toronto
Career Start Year 2012
Number of shared co-authors 1
Himisha Beltran
Dana-Farber Cancer Institute
Career Start Year 2010
Number of shared co-authors 70
Anne Haegert
University of British Columbia
Career Start Year 2008
Number of shared co-authors 23
Shancheng Ren
Shanghai Changzheng Hospital
Career Start Year 2007
Number of shared co-authors 14
Verena Sailer
Institute for Pathology, University Hospital Schleswig-Holstein
Career Start Year 2007
Number of shared co-authors 12
Svitlana Tyekucheva
Dana-Farber Cancer Institute
Career Start Year 2006
Number of shared co-authors 13
Michael C Haffner
Fred Hutchinson Cancer Center
Career Start Year 2005
Number of shared co-authors 52
Alok K Tewari
Dana-Farber Cancer Institute, Harvard Medical School
Career Start Year 2005
Number of shared co-authors 6
Katherine A Hoadley
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Career Start Year 2004
Number of shared co-authors 8
Robert H Bell
University of British Columbia
Career Start Year 2004
Number of shared co-authors 19
Adam Foye
University of California San Francisco
Career Start Year 2003
Number of shared co-authors 25
Scott A Tomlins
Rogel Cancer Center, University of Michigan Medical School ann arbor
Career Start Year 2003
Number of shared co-authors 56
Wassim Abida
Memorial Sloan Kettering Cancer Center
Career Start Year 2002
Number of shared co-authors 39
Michael Fraser
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2001
Number of shared co-authors 32
Ilsa Coleman
Fred Hutchinson Cancer Center
Career Start Year 2001
Number of shared co-authors 40
Xuhong Cao
Michigan Center for Translational Pathology.
Career Start Year 1999
Number of shared co-authors 26
Phillip G Febbo
Illumina Inc.
Career Start Year 1997
Number of shared co-authors 27
Rosina T Lis
National Cancer Institute
Career Start Year 1992
Number of shared co-authors 33
Mark A Rubin
University of Bern
Career Start Year 1990
Number of shared co-authors 59

Collaborators

Elai Davicioni
Veracyte Inc.
Co-authored papers 50
Edward M Schaeffer
Northwestern University Feinberg School of Medicine
Co-authored papers 17
Felix Y Feng
UCSF Medical Center-Mount Zion
Co-authored papers 15
Robert Jeffrey Karnes
Mayo Clinic
Co-authored papers 15
Daniel E Spratt
University Hospitals Seidman Cancer Center, Case Western Reserve University
Co-authored papers 14
Robert B Den
Thomas Jefferson University Hospital
Co-authored papers 14
Brandon A Mahal
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine
Co-authored papers 10
Paul L Nguyen
Brigham and Women's Hospital and Dana Farber Cancer Institute, Harvard Medical School
Co-authored papers 10
Mohammed Alshalalfa
University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center
Co-authored papers 10
Tamara L Lotan
Johns Hopkins University School of Medicine
Co-authored papers 8
Eric A Klein
Cleveland Clinic
Co-authored papers 8
Stephen J Freedland
Cedars-Sinai Medical Center
Co-authored papers 8
Ashley E Ross
Northwestern University
Co-authored papers 7
Timothy R Rebbeck
Center for Cancer Equity and Engagement, Dana-Farber/Harvard Cancer Center
Co-authored papers 5
Adam B Weiner
Northwestern University Feinberg School of Medicine
Co-authored papers 5
Christopher E Barbieri
Weill Cornell Medical College
Co-authored papers 5
Bruce J Trock
Johns Hopkins University School of Medicine
Co-authored papers 4
Andrea Sboner
Institute for Computational Biomedicine
Co-authored papers 4
Gerhardt Attard
The Institute of Cancer Research
Co-authored papers 3
Phuoc T Tran
University of Maryland School of Medicine
Co-authored papers 3
Sungyong You
Cedars-Sinai Medical Center
Co-authored papers 3
Tarek A Bismar
University of Calgary Cumming School of Medicine, Rockyview General Hospital
Co-authored papers 3
Arul M Chinnaiyan
University of Michigan Medical School.
Co-authored papers 3
Sheila Weinmann
Center for Health Research, Kaiser Permanente Northwest Research Center
Co-authored papers 3
Alexander W Wyatt
University of British Columbia
Co-authored papers 3
James A Proudfoot
Shiley Eye Institute, University of California
Co-authored papers 3
Amar U Kishan
University of California los angeles
Co-authored papers 3
David T Miyamoto
Massachusetts General Hospital
Co-authored papers 3
Eric J Small
University of California san francisco
Co-authored papers 3
Michael R Freeman
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center
Co-authored papers 3
Release 1.2